Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
ESMO Open|December 6, 2024
Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trialT K Choueiri, T M Kuzel, S S Tykodi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 3, 2023
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trialK N Chi, S Sandhu, M R Smith, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2020
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinomaT K Choueiri, R J Motzer, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trialT K Choueiri, L Albigès, D F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2024
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trialN M Tannir, L Albigès, D F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trialT K Choueiri, K Penkov, H Uemura, et al.
Pageof 6